Novavax COVID Vaccine Efficacy In Omicron, Delta Variants Among Unknowns Ahead Of Advisory Cmte

US FDA also says there appears to be 'causal association' of myocarditis with the vaccine, which Novavax denies.

Novavax vaccine
The FDA's Vaccines and Related Biological Products Advisory Committee will meet 7 June to discuss the Novavax COVID-19 vaccine EUA request. • Source: Shutterstock

Novavax, Inc.’s proposed COVID-19 vaccine showed strong efficacy against older variants, but the US Food and Drug Administration now wonders how it will perform against the current virus strain.

The company is seeking an emergency use authorization for a two-dose primary series of its adjuvanted recombinant spike protein nanoparticle...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet